Belgium · Delayed Price · Currency is EUR BioSenic Statistics
Total Valuation
BioSenic has a market cap or net worth of EUR 1.50 million. The enterprise value is 27.10 million.
| Market Cap | 1.50M |
| Enterprise Value | 27.10M |
Important Dates
The last earnings date was Monday, October 27, 2025.
| Earnings Date | Oct 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioSenic has 652.86 million shares outstanding. The number of shares has increased by 68.94% in one year.
| Current Share Class | 652.86M |
| Shares Outstanding | 652.86M |
| Shares Change (YoY) | +68.94% |
| Shares Change (QoQ) | +36.38% |
| Owned by Insiders (%) | 3.61% |
| Owned by Institutions (%) | 0.34% |
| Float | 579.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.72 |
| PB Ratio | -0.06 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.68 |
| EV / Sales | 265.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.21
| Current Ratio | 0.21 |
| Quick Ratio | 0.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.10 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -45.50% |
| Return on Invested Capital (ROIC) | -102.09% |
| Return on Capital Employed (ROCE) | 162.03% |
| Revenue Per Employee | 14,571 |
| Profits Per Employee | -681,143 |
| Employee Count | 7 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.49% in the last 52 weeks. The beta is -2.43, so BioSenic's price volatility has been lower than the market average.
| Beta (5Y) | -2.43 |
| 52-Week Price Change | -68.49% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 42.38 |
| Average Volume (20 Days) | 1,889,686 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSenic had revenue of EUR 102,000 and -4.77 million in losses. Loss per share was -0.02.
| Revenue | 102,000 |
| Gross Profit | 102,000 |
| Operating Income | -5.21M |
| Pretax Income | -6.71M |
| Net Income | -4.77M |
| EBITDA | -4.92M |
| EBIT | -5.21M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 391,000 in cash and 27.73 million in debt, giving a net cash position of -27.34 million or -0.04 per share.
| Cash & Cash Equivalents | 391,000 |
| Total Debt | 27.73M |
| Net Cash | -27.34M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -26.81M |
| Book Value Per Share | -0.08 |
| Working Capital | -6.32M |
Cash Flow
| Operating Cash Flow | -2.22M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -5,103.92% |
| Pretax Margin | -6,578.43% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioSenic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -68.94% |
| Shareholder Yield | -68.94% |
| Earnings Yield | -317.53% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioSenic has an Altman Z-Score of -16.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.82 |
| Piotroski F-Score | 1 |